AGRX Stock - Agile Therapeutics, Inc.
Unlock GoAI Insights for AGRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $19.59M | $10.88M | $4.10M | $749,000 | N/A |
| Gross Profit | $10.62M | $4.05M | $-6,617,000 | $467,000 | $-163,000 |
| Gross Margin | 54.2% | 37.2% | -161.4% | 62.3% | N/A |
| Operating Income | $-19,884,000 | $-41,434,000 | $-71,005,000 | $-49,053,000 | $-18,858,000 |
| Net Income | $-14,465,000 | $-25,412,000 | $-76,585,000 | $-54,686,000 | $-18,443,000 |
| Net Margin | -73.8% | -233.5% | -1867.5% | -7301.2% | N/A |
| EPS | $-6.71 | $-58.79 | $-63115.49 | $-1291.56 | $-746.20 |
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Visit WebsiteEarnings History & Surprises
AGRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 11, 2025 | — | — | — | — |
Q2 2025 | May 13, 2025 | — | — | — | — |
Q1 2025 | Mar 26, 2025 | — | — | — | — |
Q4 2024 | Nov 7, 2024 | — | — | — | — |
Q3 2024 | Aug 12, 2024 | — | $-0.68 | — | — |
Q2 2024 | May 15, 2024 | $-0.51 | $-0.63 | -23.5% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-0.92 | $-1.46 | -58.7% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-1.84 | $-1.47 | +20.1% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-3.48 | $-3.10 | +10.9% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-7.50 | $-7.76 | -3.5% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $-10.50 | $-9.00 | +14.3% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-15.00 | $-11.50 | +23.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-3.70 | $-135.50 | -3562.2% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-300.00 | $-189.00 | +37.0% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-340.00 | $-400.00 | -17.6% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $-380.00 | $-360.00 | +5.3% | ✓ BEAT |
Q3 2021 | Jul 26, 2021 | $-420.00 | $-400.00 | +4.8% | ✓ BEAT |
Q2 2021 | May 4, 2021 | $-440.00 | $-400.00 | +9.1% | ✓ BEAT |
Q1 2021 | Mar 1, 2021 | $-460.00 | $-400.00 | +13.0% | ✓ BEAT |
Q4 2020 | Nov 12, 2020 | $-360.00 | $-360.00 | 0.0% | = MET |
Latest News
Frequently Asked Questions about AGRX
What is AGRX's current stock price?
What is the analyst price target for AGRX?
What sector is Agile Therapeutics, Inc. in?
What is AGRX's market cap?
Does AGRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AGRX for comparison